226 related articles for article (PubMed ID: 29100957)
21. Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies.
Karp JE; Lancet JE
Cancer Invest; 2007 Sep; 25(6):484-94. PubMed ID: 17882662
[TBL] [Abstract][Full Text] [Related]
22. Ras family signaling: therapeutic targeting.
Cox AD; Der CJ
Cancer Biol Ther; 2002; 1(6):599-606. PubMed ID: 12642680
[TBL] [Abstract][Full Text] [Related]
23. Protein farnesyltransferase inhibitors.
Ayral-Kaloustian S; Salaski EJ
Curr Med Chem; 2002 May; 9(10):1003-32. PubMed ID: 12733981
[TBL] [Abstract][Full Text] [Related]
24. Current status of clinical trials of farnesyltransferase inhibitors.
Karp JE; Kaufmann SH; Adjei AA; Lancet JE; Wright JJ; End DW
Curr Opin Oncol; 2001 Nov; 13(6):470-6. PubMed ID: 11673687
[TBL] [Abstract][Full Text] [Related]
25. Recent advances in understanding the antineoplastic mechanisms of farnesyltransferase inhibitors.
Pan J; Yeung SC
Cancer Res; 2005 Oct; 65(20):9109-12. PubMed ID: 16230362
[TBL] [Abstract][Full Text] [Related]
26. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets.
Konstantinopoulos PA; Karamouzis MV; Papavassiliou AG
Nat Rev Drug Discov; 2007 Jul; 6(7):541-55. PubMed ID: 17585331
[TBL] [Abstract][Full Text] [Related]
27. An overview of farnesyltransferase inhibitors and their role in lung cancer therapy.
Adjei AA
Lung Cancer; 2003 Aug; 41 Suppl 1():S55-62. PubMed ID: 12867063
[TBL] [Abstract][Full Text] [Related]
28. Farnesyltransferase inhibitors: a comprehensive review based on quantitative structural analysis.
Moorthy NS; Sousa SF; Ramos MJ; Fernandes PA
Curr Med Chem; 2013; 20(38):4888-923. PubMed ID: 24059235
[TBL] [Abstract][Full Text] [Related]
29. Inhibitors of farnesyltransferase and geranylgeranyltransferase-I for antitumor therapy: substrate-based design, conformational constraint and biological activity.
Dinsmore CJ; Bell IM
Curr Top Med Chem; 2003; 3(10):1075-93. PubMed ID: 12769709
[TBL] [Abstract][Full Text] [Related]
30. Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects.
Prendergast GC; Oliff A
Semin Cancer Biol; 2000 Dec; 10(6):443-52. PubMed ID: 11170866
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of farnesyltransferase: a rational approach to treat cancer?
Puntambekar DS; Giridhar R; Yadav MR
J Enzyme Inhib Med Chem; 2007 Apr; 22(2):127-40. PubMed ID: 17518338
[TBL] [Abstract][Full Text] [Related]
32. Farnesyltransferase inhibitors.
Sebti SM; Adjei AA
Semin Oncol; 2004 Feb; 31(1 Suppl 1):28-39. PubMed ID: 14981578
[TBL] [Abstract][Full Text] [Related]
33. A novel inhibitor of farnesyltransferase with a zinc site recognition moiety and a farnesyl group.
Tanaka A; Radwan MO; Hamasaki A; Ejima A; Obata E; Koga R; Tateishi H; Okamoto Y; Fujita M; Nakao M; Umezawa K; Tamanoi F; Otsuka M
Bioorg Med Chem Lett; 2017 Aug; 27(16):3862-3866. PubMed ID: 28666734
[TBL] [Abstract][Full Text] [Related]
34. [Ras signaling pathway as a target for farnesyltransferase inhibitors--a new, promising prospects in the treatment for malignant disorders].
Helbig G; HoĊowiecki J
Wiad Lek; 2004; 57(9-10):462-7. PubMed ID: 15765763
[TBL] [Abstract][Full Text] [Related]
35. Farnesyltransferase inhibitor therapy in acute myelogenous leukemia.
Gotlib J
Curr Hematol Rep; 2005 Jan; 4(1):77-84. PubMed ID: 15610664
[TBL] [Abstract][Full Text] [Related]
36. Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects.
Prendergast GC
Curr Opin Cell Biol; 2000 Apr; 12(2):166-73. PubMed ID: 10712917
[TBL] [Abstract][Full Text] [Related]
37. Farnesyltransferase inhibitors: targeting the molecular basis of cancer.
Oliff A
Biochim Biophys Acta; 1999 May; 1423(3):C19-30. PubMed ID: 10382537
[No Abstract] [Full Text] [Related]
38. Clinical activity of tipifarnib in hematologic malignancies.
Jabbour E; Kantarjian H; Cortes J
Expert Opin Investig Drugs; 2007 Mar; 16(3):381-92. PubMed ID: 17302532
[TBL] [Abstract][Full Text] [Related]
39. Farnesyltransferase inhibitors as radiation sensitizers.
McKenna WG; Muschel RJ; Gupta AK; Hahn SM; Bernhard EJ
Semin Radiat Oncol; 2002 Jul; 12(3 Suppl 2):27-32. PubMed ID: 12174342
[TBL] [Abstract][Full Text] [Related]
40. Farnesyltransferase inihibitors in hematologic malignancies.
Harousseau JL
Blood Rev; 2007 Jul; 21(4):173-82. PubMed ID: 17293017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]